Navigation Links
Breast cancer death rates among black women not decreasing across all states
Date:2/28/2008

ATLANTA A new study from the American Cancer Society finds that while breast cancer death rates are decreasing for white women in every U.S. state, for African American women, death rates are either flat or rising in at least half the states. The study, published early online in the journal Cancer Causes and Control, finds breast cancer death rates among African American women are decreasing in only 11 of 37 states with sufficient numbers for analysis and in the District of Columbia. In the rest, death rates are either flat (24 states) or actually increasing (two states: Arkansas and Mississippi).

American Cancer Society researchers led by Carol DeSantis, MPH, analyzed mortality data from the National Center for Health Statistics (NCHS) for the years 1975 through 2004 by state and race. At the national level, death rates began to decline in 1990 for white women and in 1991 for African American women. But they decreased far slower in African American women. As a result, the gap in death rates from breast cancer between African American and white women has increased substantially. In 1991, death rates among African American women were 18 percent higher compared to white women; by 2004, they were 36 percent higher. Although breast cancer death rates have decreased in both African American and white women in the U.S. as a whole, the study found death rates have increased or remained level for African American women in 26 states.

Access to and utilization of screening as well as regional variations in the quality and timeliness of treatment likely play important roles in the disparity, write the authors, and states should focus their cancer control efforts to increase health awareness within underserved communities and to ensure that all women have access to high-quality early detection and treatment services.

Weve known for some time that these disparities exist, said Otis W. Brawley, MD, chief medical officer of the American Cancer So
'/>"/>

Contact: David Sampson
david.sampson@cancer.org
American Cancer Society
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Breast cancer subtypes linked to survival from secondary brain tumors
2. Novartis and Sony Pictures Television Internationals Latin American Advertising Sales Group Launch Partnership to Create Multi-Media Platform for Breast Cancer Awareness, Detection, and Treatment in Latin America
3. Representative Greg Harris, Senator Jacqueline Collins, Senator Iris Martinez and Fellow State Legislators to Join Susan G. Komen for the Cure in Announcing Groundbreaking Legislation to Reduce Breast Cancer Disparities; Will Hold Press Conference Friday
4. Cost of Breast Cancer Can Include Paycheck
5. Photo: Beverly Hills Liposculpture Specializes in Scarless Breast Reduction Dr. Alan Bittner Reduces Female Breasts by up to 50%
6. Hormone therapy increases frequency of abnormal mammograms, breast biopsies
7. LA BioMed study finds hormone therapy increases frequency of abnormal mammograms, breast biopsies
8. Test can reduce recurrence of breast cancer
9. FDA OKs Avastin for Advanced Breast Cancer
10. NIST, NCI, SAIC partner on new method for detecting HER2 breast cancer
11. Chemotherapy After Breast Cancer Surgery Effective for Older Women, Too
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:New National Pharmaceutical Council Report Provides Guidance on Evaluating Comparative Effectiveness Studies 2Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 2Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 3Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 4Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 5Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 6Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 7Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 8Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 9Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 10Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 11Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 12Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 13Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 14Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 15Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 16Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 17Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 18Cubist Pharmaceuticals Becomes First Company to Implement Integrated Reprints Desk Document Delivery and QUOSA Scientific Literature Workflow Solution 2Cubist Pharmaceuticals Becomes First Company to Implement Integrated Reprints Desk Document Delivery and QUOSA Scientific Literature Workflow Solution 3Using Your Immune System to Fight Cancer 58734 1U S Census Bureau Daily Feature for Oct 2 58730 1Intercept Pharmaceuticals FXR Agonist INT 747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty 5182 1Intercept Pharmaceuticals FXR Agonist INT 747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty 5182 2